A number of N 4-hydroxy and N 4-amino derivatives of 3'-azido-2',3'-dideOxY-5-methyICyMSine have been synthesized and tested for anti~ral activity against HIV-1 and HIV-2. The N 4-phenylamino and N 4 _" dimethylamino analogues show marked anti-HIV activity which is comparable to that of AZT.
Introduction
Since 3'-azido-3'-deoxythymidine (AZT) was shown to be an effective inhibitor of the reverse transcriptase of human immunodeficiency virus (HIV) there have been many attempts to prepare analogues with improved activity (Nasr et al., 1990 and references therein) . Most of these have been modified on the sugar residue, and, while base-modified analogues have been tested, there have been very few compounds prepared with modifications at C 4 (Giner-Sorolia et al., 1968; De Napoli et al., 1991) . Cytidine derivatives containing electronegative elements attached to the amino group have tautomeric constants closer to unity than that of the parent nucleoside and therefore have the potential, in hydrogen-bonding terms, to behave as either a cytosine or a uracil (thymine) at the demand of the system (Brown et al., 1968; Anand et al., 1987) . Such nucleosides are designated as having ambivalent hydrogen-bonding behaviour, and the advantage of such derivatives is that they might be incorporated opposite either a guanine or an adenine during transcription, giving a greater chance of viral growth inhibition. Received 8 July, 1994; revised 9 August, 1994; accepted 24 August, 1994 . *For correspondence. Tel. 0223 402371; Fax 0223 412282.
We were interested in preparing N 4-aminoand N 4-oxycytidine analogues related toAZT and the uracil analogue AZdU, 1 (R 2 = CH s or H; X=O or N) ( Fig. 1) . N 4-Hydroxycytidine derivatives related to AZT and AZdU have been reported (Herdewijn et al., 1988; Czernecki et al., 1993) , and the AZT analogue (1b; R 2=CH s, XR 1=OH) has been shown to have a distinct and selective anti-HIV activity, with an EC so of 1.5J..lM and a CCso of 92 J..lM (Herdewijn et al., 1988) .This has been confirmed by our present findings (Table 1) .
Results
Modified nucleosides were prepared from 3 ( Fig. 1 ) by nucleophilic displacement of triazole at C 4 . The triazoles were prepared from 5'-tritylnucleosides (2, R 1=H, CH s; R 2=Ph sC) (Chu et al., 1989) , or, by preference, from the 5'-benzoates (2, R 1=H, CH s; R 2=PhCO) (Czernecki and Valery, 1990) . These were used as starting materials for the formation of all the C 4-modified analogues. Typically, the triazolo compound was treated with the base hydrochloride in pyridine overnight and then deprotected with methanolic ammonia (R 2=PhCO) or With 80% aqueous acetic acid (R 2=Ph sC).
Treatment of the triazoles 3 with hydroxylamine hydrochloride or methoxyamine hydrochloride gave, after removal of the 5'-protecting group, 1a (XR 1=OCH s, R 2=H), 1b (XR 1=OH, R 2=CH s) and 1c (XR 1=OCH s, R 2=CH s). The products formed by the reaction with hydroxylamine on the 5'-trityl derivatives were also acetylated to give. after acidic deprotection, the N 4-acetoxy products 1d (XR 1=OCOCH s, R 2=H) and 1e (XR 1=OCOCH s, R 2=CH s). Removal of the trityl group from the two triazoles 1 (R 1=H, CH s, R 2=Ph sC) with aqueous acetic acid gave low yields of the desired 3a (R 1=R2=H) and 3b (R 1=CH s, R 2=H), the major product in both cases resulting from the hydrolysis of the triazolo group.
Apart from 1b, none of these compounds,showed any anti-HIVactivity. It might have been expected that the triazole 3b would have been active due to its possible hydrolysis in situ to AZT, but this appeared not to be the case. It is also interesting to note that, whilst the N 4-hydroxy derivative related to AZT was active (see later), the N 4 _ methoxy derivative showed no sign of activity.
As we had seen no significant sign of anti-HIV activity with N 4-hydroxy derivatives, we turned our attention to AZT AntiViral activity
The compounds 1a-1e, 4b, 5a and 5b were each tested against VZV and CMV (tests carried out by R. Snoeck and G. Andrei with the assistance of A. Camps), but none of these compounds exhibited any activity against these viral targets. All of the final products described were tested against HIV-1, and, whilst it became clear that none of the derivatives related to AZdU showed any anti-HIV activity, some of the AZT analogues did show such activity. The triazolo derivative and the N 4-oxycytidine analogues showed little or no activity; however, we found that all the N 4-aminocytidine analogues of AZT showed anti-HIV activity. The results are shown in Table 1 . 4b and 5b were also active against HIV-2 in MT-4 cells with EC 5 0 values of 0.015 and 0.060 11M, respectively (AZT=0.0025 11M); both compounds were found to be less toxic (CC 5 0 68.3 and 8.56 11M, respectively) than AZT (CC 5 0=4.61 11M). From these results it is therefore clear that some of the N 4-aminocytidine analogues have selectivity indices comparable to that of AZT. Like AZT, none of the compounds showed any anti-HIV-2 activity in CEMITK-cells, indicating that, like AZT, they require phosphorylation to the active metabolites.
To investigate the possibility that these compounds were being deaminated by cytidine deaminase to AZT, the anti-HIV-1 activities of 4b and 4c were assessed in the presence and absence of tetrahydrouridine (THU), a cytidine deaminase inhibitor (Yusa et al., 1992) . In C8166 cells with HIV-1 IIIB, the presence of 400 11M THU seemed to result in a general reduction in both the estimated cell growth (for uninfected cells as determined by the MIT N 4-amino derivatives. A number of simple N 4-aminocytidines had been synthesized earlier by Hayatsu and coworkers by bisulphite-catalysed displacement of ammonia from cytidine by hydrazines (Negishi et al., 1983; Nomura et al., 1985) . The reaction is inhibited by a 5methyl substituent, so we investigated instead the triazoles as active intermediates. Treatment of the triazole 3 (R 1=H, R 2=Ph sC) with anhydrous hydrazine in dichloromethane gave rise to a new polar product, and when the reaction was monitored by NMR. it was essentially complete within a few seconds. The product proved very difficult to isolate and yields were very low. We took the view that acid-catalysed removal of the protecting group would be preferred, since protonation of the hydrazino residue would stabilize it. However, when the trityl group was removed, the desired final product 4 (R 1=R2=Rs=H) could not be purified due to its very polar nature and, we believe, its ready oxidation. Even when the trityl-deprotected triazole 3 (R:=R 2=H) was treated with hydrazine, whilst the reaction could be seen to have gone to completion by TLC monito~hg, the product could not be isolated or adequately chilfacterized as the free base, the hydrochloride salt or its acetate. This was found to be the case in both the thymine and the uracil series. Additionally, we were unable to isolate a product when the triazolo derivatives were treated with semicarbazide (Hayatsu, 1976) . The evidence again suggested that oxidative degradation was occurring. In retrospect it may be that the alternative synthetic route using bisulphite as catalyst may have provided the reducing conditions suitable for preventing such decomposition.
When 1,1-dimethylhydrazine was used, the product could be easily isolated and characterized. Thus reaction with 3 (R 1=H, R 2=Ph sC) followed by deprotection with aqueous acetic acid gave 4a (R 1=R2=CH s, X=N s), and reaction with 3 (R 1=H, R 2=PhCO) followed by methanolic ammonia gave 4b (R 1=CH s , R 2=H, X=N s ). When methylhydrazine was used, the products obtained were found by NMR to be those of displacement of the triazolo group solely by the secondary amino-function. This was confirmed by the presence of an exchangeable two-proton NMR signal. The greater reactivity of the methylamino residue has been observed by others {Butler et al., 1971}. The two products obtained after deprotection of the 5'hydroxyl group were 5a (R=H) and 5b (R=CH s).
With phenylhydrazine, the reaction with 3 (R 1=CH s, R 2=PhCO) was slower and gave rise to a number of minor products, but the major product was characterized as 4c (R 1=H, R 2=Ph, RS=CH s , X=N s ). Similarly, reaction with 2-hydroxyethylhydrazine gave a number of by-products, but the desired product was obtained to give, after deprotection, 4d (R 1=H, R 2=CH 2CH20H, RS=CH s, X=N s). In addition, the N 4,N4-dimethyl-5-methylcytosine analogue of AZT 6 was prepared for comparison. method) and the gp120 antigen levels (for infected cells). This gives the impression that THU reduces the EC 5 0 values, although this may be due to a slight toxicity of the latter. In U937 cells with HIV-1 4 55 , the presence of 400flM THU seemed to have little effect upon antigen levels. These results lead us to believe that the N 4 -aminocytidine derivatives may not be deaminated in situ to AZT, although further work is necessary to confirm this. If demonstrated conclusively, these compounds would form a new class of anti-HIV-1 agents. However, in view of the uncertainty on this point, our original view that the N 4 -amino analogues would act as cytosines or thymines at the demand of the template base cannot be usefully discussed.
Discussion
A new series of AZT analogues has been prepared. N 4 _ amino-2'-deoxycytidine analogues were all shown to have anti-HIV-1 activity. In the case of the N 4 -dimethylamino and the N 4 -phenylamino-2'-deoxycytidine analogues, the anti-HIV activity is comparable to that of AZT. Whilst it has not been demonstrated conclusively, these compounds do not appear to be deaminated to AZT, and if this is so these compounds constitute a new class of anti-HIV-1 agents.
Materials and Experimental procedures: chemistry
1H-NMR spectra were obtained on a Bruker WM-250, with samples dissolved in dS-OMSO. Mass spectra were recorded on a Kratos MS890 spectrometer. Ultraviolet spectra were recorded on a Perkin-ElmerLambda 2 spectrophotometer, in 1% aqueous methanol unless otherwise stated. Thin layer chromatography (TLC) was carried out on pre-coated F 2S4 silica plates, and column chromatography was performed with Merck kieselgel 60. Melting points were measured using a Gallenkamp melting point apparatus and are uncorrected. Unless otherwise stated, reactions were worked up as follows: after removal of the solvent the product was dissolved in chloroform and washed with aqueous sodium bicarbonate solution. The combined organic fractions were dried over sodium sulphate and evaporated.
The phosphorus tris-triazolide solution (Webb and Matteucci, 1986 ) was prepared as follows: 1,2,4-triazole (3.2 g, 46 mmol) was suspended in 75 ml acetonitrile and cooled to c-c. Phosphoryl chloride (1 ml, 10.7mmol) was added over 2 min and the solution stirred for 10 min at 0 DC and then triethylamine (7.5 ml, 54 mmol) was added over i s min and the solution stirred for 20 min at 0 DC.
Oetritylations were effected by heating of a solution of the 5'trityl derivative for 30 min in 80% acetic acid followed by removal of the solvent, unless otherwise stated.
To a solution of the phosphorus tris-triazolide was added 2 (R 1=H, R 2=Ph 3C) (Chu etal., 1989) (1.17g, 2.36mmol) in ace-tonitrile (10 ml), and the solution was stirred for 2 h at room temperature. After work-up, the brown gum was chromatographed (CHCI 3 ) to give a pale yellow foam, yield 
To a solution of the phosphorus tris-triazolide was added 5'-0benzoyl-3'-azido-2',3'-dideoxythymidine (Czernecki and Valery 1990) (5.1 g, 13.7 rnmol) in acetonitrile (25 ml 
1-
To a solution of the phosphorus tris-triazolide was added 2 (R 1=CH 3 , R 2=Ph 3C) (Chu et al., 1989) in acetonitrile (25ml), and the solution was left to stir at room temperature overnight. Work-up gave a pale brown foam which was chromatographed (CHCI 3 ) to give a white foam, yield 0.91 g, 87%. 1H-NMR a The triazole 3 (R 1=H, R 2=Ph aC) (300 mg, 0.55 mmol) was dissolved in pyridine (10 ml), methoxyamine hydrochloride (230 mg, 2.7 mmol) was added, and the solution was stirred at room temperature overnight. After work-up, the product was chromatographed (CHCl a ) to give a yellow foam, yield 236 mg, 82%. 1H-NMR a (ppm) 2.24-2.46 (2H, m, H:2' , H-2"), 
N 4 -Methoxy-5-methyl-3'-azido-2', 3'-dideoxycytidine 1c
To a solution of the triazole 3 (R 1=CH a, R 2=Ph a C) (300 mg, 0.S4 mmol) in pyridine (10 ml) was added methoxyamine hydrochloride (220 mg, 2.7 mmol) and the reaction was stirred at room temperature overnight. The 5'-trityl derivative was worked up and chromatographed (CHCl a) to give a white foam, yield 254mg, 88%. 1H-NMR a(ppm) 2.23-2.49 (2H, rn, H-2', H-2"), 3.21-3.69 (2H, m, H-5', H-5"), 3.70 (3H, s, OCH a), 3.79-3.85 (1H, rn, H-4'), 4.S1-4.59 (1H, rn, H-3'), 6.11 (1H, t, J= 6.6Hz, H-1'), 6.87 (1H, s, H-6), 7.26-7.43 (15H, rn, trityl CH), 9.85 (1H, s, NH). The above compound was detritylated and chromatographed (CHCIa/1 % MeOH) to give 1c as a white solid, yield 85mg, 61%. M.p. 137-138°C (Lit. 134-135°C). m/z Antiviral activity of N 4 -aminocytidine derivatives 13 296 (M+): Ace. mass found, 296.1229, C11H16N604, Dev. = -1.4ppm. UV Amax (nm) 241.5 (E=19800), 272.5 (E=18400), Amin 261, pH 1 Amax 226.5 (E=9600), 282.5 (E=11 800) Amin 254, pH 12 Amax 264.5 (E=13600). 1H-NMR a(ppm) 1.71 (3H, s, CH a ), 2.11-2.37 (2H, m, H-2', H-2"), 3.56-3.60 (2H, m, H-5', H-5"), 3.70 (3H, s, OCH a ) , 3.74-3.79' (1 H, s, H-4'), 4.33-4.40 (1H, rn, H-3') , 5.14 (1H, t, OH), 6.07 (1H, t, J= 6.8Hz, H-1'), 6.97 (1H, s, 9.78 (1H, s, NH) .
The triazole 3 (R 1=H, R 2=Ph aC) (300mg, 0.6mmol) was dissolved in pyridine (10 ml 
The triazole 3 (R 1=H, R 2=Ph aC) (300 mg, 0.5 mmol) was dissolved in pyridine (10 ml), 1,1-dimethylhydrazine (0.2 rnl, 2.7 mmol) was added, and the solution was stirred at room temperature overnight. The solution was worked up and chromatographed (CHCIa/1 %MeOH) to give a pale yellow foam, yield 120mg, 41%. 1H-NMR a (ppm) 2.31-2.37 (2H, m, H2', H2"), 3.03 (6H, s, 2 x NCH a), 3.27-3.31 (2H, m, H5', H5"), 3.86-3.92 (1H, m, H4'), 4.43-4.51 (1H, m, H3'), 5.85 (1H, d, J=7.8 Hz, H6), 6.09 (1H, t, J=5.9 Hz, H1'), 7.25-7.43 (15H, rn, trityl CH), 7.74 (1H, d, J=7.8 Hz, H5). The above product (100 mg, 0.2 mmol) was detritylated and chromatographed (CHCl s/5%MeOH) to give a white powder, yield 33 mg, 60%. M.p. 141-143 DC. m/z M+ = 238 (M -NN(CHsb)W. UV "-max (nm) 215 (sh) (£=11 000),278 (£=13500), "-min 239, pH 1 "-max 219 (£=8700), 286.5 (£=15900) I min 245, pH 12 "-max 278.5 (£=13700). 1H-NMR a (ppm) 2.24-2.31 (2H, rn, H-2', H-2"), 3.03 (6H, s, NN(CHsb), 3.35-3.64 (2H, rn, H-5', H-5"), 3. 83-3.88 (2H, m, H-5', H-5"), 4.31-4.38 (1H, m, H-3') , 5.22 (1H, t, OH), 6.07 (1H, d, J=7.7 Hz, H-6), 6.09 (1H, t, J=6 Hz, H-1'),7.88 (1H, d, J=7.7 Hz, .
The triazole 3 (R 1=CH s, R 2=PhCO) (300 mg, 0.7 mmol) was dissolved in 10 ml pyridine, dimethylhydrazine (270 Ill, 3.6 mmol) was added, and the solution was stirred at room temperature overnight. The product was worked up as usual to give a yellow foam. This was dissolved in methanolic ammonia (25 ml) and stirred at room temperature overnight. Phenylhydrazine hydrochloride (1 g, 7 mmol) was added to a solution of the triazole 3 (R 1=CH s, R 2=PhCO) (0.6 g, 1.4 mmol) in pyridine (25 ml) and the solution was stirred at room temperature under argon for 24 h. The solution was worked up and chromatographed (CHCl s) to give a brown foam, yield 0.34 g, 52%. The product (300 mg, 0.65 mmol) was then stirred at room temperature overnight in methanolic ammonia (25 ml). TLC showed a major and several minor products. The solution was evaporated and chromatographed (CHCIs/1% MeOH) to give a pale brown foam, yield 52 mg, 22%. m/z 342 (M-CHsr, 267 (M-NHPhr. UV "-max (nm) 286 (£=11 400), Xrnln 244.5, pH 1 "-max 295 (£=10300) "-min 244, pH 12 "-max 289 (£=10900).
1H-NMR a(ppm) 2.05 (3H, s, CH s), 2.23-2.37 (2H, m, H-2', H-2"), 3. m, m, m, m, OH) , 6.10 (1H, t, J= 6.1 Hz, H-1'), 7. m, Phenyl CH), 7.79 (1H, s, 8.60 (1H, s, NH), 11.32 (1H, s, NH) . R 1=H, Ff!=CH 2CH20H, R 3=CH3 , X=N 3 ) To a solution of the triazole 3 (R 1=CH s, R 2=PhCO) (0.5 g, 1.2 mmol) in pyridine (25 ml) was added 2-hydroxyethyl hydrazine (240 Ill, 3.55 mol), and the solution was stirred at room temperature overnight. The solution was worked up and chromatographed (CHCIs/3% MeOH) to give a white foam, yield 0.34 g, 67%. This was dissolved in methanolic ammonia (25 ml) and stirred at room temperature. TLC showed a number of by-products. The major product was isolated, after work-up, by chromatography (CHCIs/5% MeOH) to give 4d as a clear gum, yield 30 mg, 12%. m/z 184 (M-azidosugarr, ace, mass on 184 found 184.0966, C7H12N402, dev. 3.2 ppm. 1H-NMR a (ppm) 2.21 (3H, s, CH s), 2.23-2.35 (2H, m, H2', H2"), 3.45-3.79 (6H, rn, H5', H5", 2 x CH 2), 3. 80-3.83 (1H, m, H4'), 4.32-4.39 (1H, rn, H3'), 4.84, 4 .88 (2H, 2 x br. s, 2 x NH), 5.21 (1H, t, OH), 6.06 (1H, t, J=6.4 Hz, H1'), 7.53 (1H, s, H6) . -methyl-3'-azido-2',3'-dideoxycytidine (5a; R=H,X=N 3 ) The triazole 3 (R 1=H, R 2=OH) (300 mg, 0.5 mmol) was dissolved in pyridine (10 ml), methylhydrazine (88 Ill, 1.5 mmol) was added, and the solution was stirred at room temperature overnight. After work-up the product was chromatographed (CHCl s) to give the 5'-trityl derivative as a white foam, yield 185mg, 65%. 1H-NMR a (ppm) 2.31-2.42 (2H, rn, H2', H2"), N 4 - R=CH 3 , X=N 3 ) The triazole 3 (R 1=CH s, R 2=PhCO) (0.6 g, 1.4 mmol) was dissolved in dichloromethane (20 ml), methylhydrazine (151 Ill, 2.8 mmol) was added and the solution was stirred at room temperature for 2 days. The solvent was removed and the product chromatographed (CHCIs/1%MeOH) to give a white foam, yield 0.34 g, 60%. This was then dissolved in methanolic ammonia (25 ml) and stirred at room temperature for 5 h. The solvent was removed and the product chromatographed (CHCIs/2%MeOH) to give a white solid, yield 154mg, 61%. 2, 4triazolo) -5-methylpyrimid-2-one 1,2,4-Triazole (8.85 g, 128 mmol) was suspended in acetonitrile (50 ml) at O°C, phosphoryl chloride (2.8 ml, 30mmol) was added over 2 min and the solution was stirred at O°C for 10 min. Triethylamine (21 ml, 150 mmol) was then added over 5 min and the solution stirred at O°C for a further 20 min. 3',5'-Di-O-acetyl-2'-deoxythymidine (2.26 g, 6.9 mmol) in acetonitrile (25 ml) was then added and the solution stirred at room temperature overnight. Work-up of the solution gave a brown gum which was chromatographed (CHCIJ1 %MeOH) to give a white foam, yield 2.40 g, 92%. 1H-NMR a(ppm) 2.05, 2.08 (6H, 2 x s, 2 x CH 3CO), 2.34 (3H, 2, CH 3 ) , 2.40-2.62 (2H, rn, H2', H2"), 3.31 (1H, m, H4'), 4.32-4,37 (2H, m, H5', H5"), 5.22-5.25 (1H, m, H3'), 6.17 (1H, t, J=7 Hz, H1'), 8.25 (1H, s, H6), 8.38, 9.33 (2H, 2 x s, R=CH 3 , X=OH) To a solution of 1-(3,5-di-O-acetyl-2-deoxy-~-D-ribofurano syl)-4-(1,2,4-triazolo)-5-methylpyrimid-2.pne 0.4 g, 1.1 mn:ol) in dichloromethane (20 ml) was a~aed rnethylhydrazlne (170 Ill, 3.2 mmol), and the solution was stirred at room temperature overnight. This was worked up to give a white foam which' was stirred at room temperature overnight in methanolic ammonia (10 ml). The solvent was removed and the product crystallized from methanol to give a white powder, yield 223mg, 78%. M.p. 201-203°C. UV Amax (nm) 222 (sh) (E=6200), 289 (E=10600), Amin 243, pH 1 Amax 222.5 (E=6800), 298 (E=11700) Amin 253, pH 12 Amax 289.5 (E=10900). 1H-NMR a(ppm) 1.96-2.04 (2H, m, H2', H2"), 2.11 (3H, s, CH 3 ) , 3.18 (3H, s, NCH 3 ) , 3.53-3.60 (2H, m, H5', H5"), 3.72-3.76 (1H, m, H4'), 4.19-4.23 (1H, m, H3'), 4.83 (2H, s, NH 2 ) , 5.00 (1H, t, 5'-OH), 5.17 (1H, d, 3'-OH), 6.14 (1H, t, J=6.3 Hz, H1'), 7.54 (1H, s, H6). ,~,5-Trimethyl-3'-azido-2',3'-dideoxycytidine 6
To a solution of 1-(3,5-di-O-acetyl-2-deoxy-~-D-ribofuranosyl) 4-(1,2,4-triazolo)-5-methylpyrimid-2-one (0.5 g, 1.2 mmol) in acetonitrile (20 ml) was added dimethylamine (25% w/v in water, 0.69 ml, 3.6 mmol), and the solution was stirred at room temperature for 6 h. The solvent was removed and the product stirred with methanolic ammonia (10 ml) overnight. The solvent was evaporated and the product chromatographed (CHC1 3/2% MeOH) to give a white powder, yield 0.27 g, 78%. M.p: 154-156°C. m/z 294 (M+). UV Amax (nm) 223 (sh) (E=7600), 287.5 (E=11 900), Amin 243, pH1 Amax 225 (E=8300), 300 (E=13700) Amin 255, pH12 Amax 287.5 (E=12500). 1H-NMR a (ppm) 2.12 (3H, s, CH 3 ) , 2.24-2.30 (2H, m, H2', H2"), 3.07 (6H, s, N(CH 3 b ), 3.59-3.65 (2H,-m, H5', H5"), 3.82-3.84 (1H, m, H4'), 4.35-4.38 (1H, m, H3'), 5.23 (1H, t, OH), 6.07 (1H, t, J=6.4 Hz, H1'),7.64 (1H, s, H6).
Materials and Experimental procedures: virology
Varicella-zoster virus (VZV) assays were carried out in human embryonic lung (HEL) cells against TK+ (OKA and YS strains) Antiviral activity of N 4 -aminocytidine derivatives 15 and TK-(07/1 and YS/R strains). Virus input was 20 plaque forming units (p.f.u.); acyclovir served as the reference compound.
Cytomegalovirus (CMV) assays were carried out in HEL cells using the AD-169 and Davis strains. Virus input was 100 p.f.u. Ganciclovir served as the reference compound.
Anti-HIV-1 activity assays were carried out in C8166 cells with HIV-1 IIiB. Cell viability and cytotoxicity were measured by MTT-formazan, and viral antigen gp120 levels were estimated in the infected cell culture supernatants by ELISA. Anti-HIV-2 activity assays were performed in MT-4, CEM/O or CEMITKcells with HIV-2 ROD.
Experiments using tetrahydrouridine (THU) as a cytidine deaminase inhibitor were carried out in C8166 cells with HIV-1 IIiB and in U937 cells with HIV-1 455.
